High-sensitivity troponins - difficult friends in acute coronary syndromes

Klingenberg, Roland; Matter, Christian M; Wyss, Christophe; Hof, Danielle; von Eckardstein, Arnold; Lüscher, Thomas F

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-74385

Originally published at:
High-sensitivity Troponins—Difficult Friends in Acute Coronary Syndromes

Roland Klingenberg,1 Christian M Matter,2 Christophe Wyss,1 Danielle Hof,4 Arnold von Eckardstein1 and Thomas F Lüscher6

1. Clinical Fellow, Department of Cardiology/Cardiovascular Research, University Hospital Zurich; 2. Attending Physician, Department of Cardiology/Cardiovascular Research, University Hospital Zurich and Zurich Centre of Integrated Human Physiology, University of Zurich; 3. Attending Physician, Department of Cardiology/Cardiovascular Research, University Hospital Zurich; 4. Clinical Fellow, Department of Clinical Chemistry, University Hospital Zurich; 5. Professor, Department of Clinical Chemistry, University Hospital Zurich and Zurich Centre of Integrated Human Physiology, University of Zurich; 6. Professor, Department of Cardiology/Cardiovascular Research, University Hospital Zurich and Zurich Centre of Integrated Human Physiology, University of Zurich, Zurich, Switzerland

Abstract

The introduction of novel high-sensitivity cardiac troponin (hs-cTn) assays has made it possible to measure cardiac troponin levels that are up to 10-fold lower than those detectable by conventional cardiac troponin (cTn) assays. With such novel assays, an elevated risk of major adverse cardiovascular events was noted across the continuum of cTn levels, with an incremental risk of increasing levels even in healthy individuals, but also in patients with stable coronary artery disease, congestive heart failure or acute coronary syndrome (ACS). The rapid triage of patients presenting to the accident and emergency department with chest pain is critical to ensure optimal management, and the novel hs-cTn assays provide a valuable tool for a more rapid exclusion of acute myocardial infarction (AMI), with a higher sensitivity, negative predictive value and diagnostic accuracy compared with conventional cTn assays. The associated decrease in specificity and positive predictive value for the diagnosis of AMI can be overcome by serial measurements to assess the absolute and relative increases in cTn levels. This article provides a contemporary overview of the role of hs-cTn in the detection of individuals with subclinical disease, diagnosis of ACS, risk stratification and clinical management. Furthermore, aspects of uncertainty, such as cut-offs, and the role of hs-cTn for clinical decision-making are addressed.

Keywords

Cardiac troponins, acute coronary syndromes, diagnosis, risk stratification, clinical management

Disclosures: Roland Klingenberg, Christian M Matter, Christophe Wyss, and Danielle Hof have no conflicts of interest to declare. Arnold von Eckardstein has received speaking honoraria from Roche Diagnostics and Beckman Coulter Inc. Thomas F Lüscher has received speaking honoraria, consultancy fees and institutional research grants from Abbott, AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, Boston Scientific, CSL, Johnson & Johnson, Eli Lilly, Medtronic, Merck, Pfizer, and St Jude Takeda. The authors have received a restricted grant from Roche Diagnostics, Switzerland, as well as support from the Swiss National Research Foundation Sonderprogramm Universitätsmedizin (SPUM 33CM03-124112), the Swiss Heart Foundation, the Fondation Leducq and a strategic alliance with Pfizer Inc. and the Zurich Heart House (Foundation for Cardiovascular Research, Zurich).

Received: 23 January 2012 Accepted: 26 May 2012 Citation: US Cardiology, 2012;9(2):121-5

Correspondence: Roland Klingenberg, Department of Cardiology/Cardiovascular Research, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland. E: roland.klingenberg@usz.ch

Major reductions in death rates in acute coronary syndromes (ACS) were achieved with the implementation of percutaneous coronary intervention allowing rapid coronary reperfusion.1 Nonetheless, mortality and morbidity remain substantial during the ensuing five years after an acute coronary syndrome (ACS).2 Indeed, between 1987 and 2006, survival among 30-day survivors of ACS has not improved despite a marked reduction in early mortality and a substantial shift in the epidemiology of MI with the introduction of cardiac troponins in laboratory diagnostic tests.3 Thus, improvements in early diagnosis, risk stratification and clinical management of patients presenting with ACS are needed. ACS comprises the distinct entities of unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI) and ST elevation myocardial infarction (STEMI), as defined by the current European Society of Cardiology (ESC) and American Heart Association/American College of Cardiology (AHA/ACC) guidelines.4-6 Among the tools available for diagnosis, risk stratification, and clinical management of ACS, biomarkers figure prominently.7 Troponins as specific markers of myocardial necrosis constitute the main circulating biomarker for the differentiation between UA and NSTEMI,8 and an early invasive strategy in high-risk patients identified by elevated troponin levels is associated with better short- and long-term outcomes.8

The development of novel high-sensitivity cardiac troponin (hs-cTn) assays for the quantification of cardiac troponins in the circulation at plasma concentrations at the 99th percentile or lower in a reference population with a coefficient of variance of ≤10 % made it possible to fulfil the quality criteria postulated by the Joint ESC/ACCF (American College of Cardiology Foundation)/AHA/WHF (World Heart Federation) Task Force for the Redefinition of Myocardial Infarction.9 In addition to determining the absolute plasma concentrations of cardiac troponins, the rise or fall of
Acute Coronary Syndromes

Cardiac troponin levels detectable by the novel hs-cTn assays are up to 10-fold lower than those detected by the conventional cTn assays. Thus, the lower limit of detection of the new high-sensitivity troponin T (hs-cTnT) assay by Roche (Elecsys Troponin T®, Roche Diagnostics, Mannheim, Germany) is 0.005 μg/l compared with 0.01 μg/l for the conventional fourth-generation assay corresponding to 0.03 μg/l for the high-sensitivity cardiac troponin T (hs-cTnT) assay.

Of note, three large population-based cohort studies in apparently healthy individuals using the same hs-cTnT assay showed detectable cardiac troponin T (cTnT) concentrations in a substantial proportion of subjects: 25 % in the Cardiovascular health study,16 66 % in the Dallas heart study,17 and 66.5 % in the Atherosclerosis risk in communities (ARIC) study.18 Importantly, elevated hs-cTnT levels were also associated with increased mortality in all three studies.

Among those three studies, the ARIC study had the strongest association of hs-cTnT levels with fatal coronary events (odds ratio [OR] 7.59, 95 % confidence interval [CI] 3.78–15.25), hospitalization for congestive heart failure (OR 5.95, 95 % CI 4.47–7.92) and overall mortality (OR 3.96, 95 % CI 3.21–4.88), but weaker associations with non-fatal coronary events and coronary revascularizations (OR 2.29, 95 % CI 1.81–2.89). This may indicate that elevated high-sensitivity troponin (hs-Tn) levels primarily predict structural heart disease events rather than atherothrombotic events. Indeed, conflicting evidence exists as to whether stress-induced ischemia is associated with detectable troponin levels using hs-cTn assays.19,20 Beyond silent ischemia, coronary microvascular dysfunction, structural and functional myocardial alterations as well as apoptosis may account for troponin release from cardiac myocytes. In patients at high risk of cardiovascular events, such as those with congestive heart failure21 or stable coronary artery disease,22 troponin T levels detectable with the high-sensitivity assay but not with the fourth-generation conventional assay were independently associated with adverse cardiovascular outcomes, but not with non-fatal coronary events.

Diagnosis of Patients with Acute Coronary Syndrome

For STEMI, an electrocardiogram (ECG) provides enough information for decision-making, but the distinction between NSTEMI and UA or non-cardiac chest pain requires sensitive and specific biomarkers. Although troponins outweigh other markers of myocardial necrosis in several aspects, conventional cTn tests are disadvantageous in that they can detect a rise in circulating troponin plasma concentration only three to four hours after myocardial damage occurs – similar to creatine kinase myocardial band (CK-MB). Previously, optimal sensitivity of conventional cTn tests could only be achieved six or even nine hours after the onset of myocardial necrosis.4 Therefore, conventional cTn tests provide an insufficient sensitivity to exclude (‘rule out’) AMI (i.e., NSTEMI) in the immediate phase after the onset of chest pain. Accordingly, previous joint guidelines of the AHA and National Academy of Clinical Biochemists recommended the retest of troponin levels in ‘troponin-negative’ NSTEMI patients for at least six hours.23

This gap can now be narrowed by the use of novel hs-Tn assays. Owing to the improved sensitivity (∼70 % with cTn assays and ∼90 % with novel
High-sensitivity Troponins—Difficult Friends in Acute Coronary Syndromes

**Figure 3: Global Registry of Acute Coronary Event Risk Score in Patients with Acute Coronary Syndromes for All-cause Mortality from Discharge to Six Months**

<table>
<thead>
<tr>
<th>Medical history</th>
<th>Findings at initial hospital presentation</th>
<th>Findings during hospitalization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years</td>
<td>Resting heart rate (beats per minute)</td>
<td>Initial serum creatinine (mg/dl)</td>
</tr>
<tr>
<td>≤29</td>
<td>≤49.9</td>
<td>0</td>
</tr>
<tr>
<td>30–39</td>
<td>50–69.9</td>
<td>0.4–0.79</td>
</tr>
<tr>
<td>40–49</td>
<td>70–89.9</td>
<td>0.8–1.19</td>
</tr>
<tr>
<td>50–59</td>
<td>90–109.9</td>
<td>1.2–1.59</td>
</tr>
<tr>
<td>60–69</td>
<td>110–149.9</td>
<td>1.6–1.99</td>
</tr>
<tr>
<td>70–79</td>
<td>150–199.9</td>
<td>2–3.99</td>
</tr>
<tr>
<td>80–89</td>
<td>≥200</td>
<td>≥4</td>
</tr>
<tr>
<td>≥90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>History of congestive heart failure</td>
<td>36</td>
<td>Elevated cardiac enzymes</td>
</tr>
<tr>
<td>History of myocardial infarction</td>
<td>15</td>
<td>No in-hospital percutaneous coronary intervention</td>
</tr>
</tbody>
</table>

The figure shows the various parameters, including conventional cardiac troponin, that make the Global Registry of Acute Coronary Event (GRACE) risk score. Adapted from Eagle, et al., 2004.32

hs-cTn assays), a higher negative predictive value is established with a negative hs-cTn test result.17,18 As a consequence, the most recent ESC guidelines for the diagnosis of ACS reduce the time interval for retesting in initially hs-cTn-negative ACS patients to three hours4 (see Figure 2).

However, as a trade-off, the increase in sensitivity is accompanied by a diminished specificity for MI (97% with cTn assays and 91% with novel hs-cTn assays) and a reduced positive predictive value (85% with cTn assays and 77% with novel hs-cTn assays).17,18 Interestingly, in the ARIC population study, 7.4% of individuals had cTnT levels ≥0.0014 μg/l—the current threshold level for acute MI (AMI) issued by the manufacturer—and the 99th percentile value was substantially higher at 0.03 μg/l,12 calling into question the versatility of a single cut-off across different ages, gender and renal function. In fact, the diagnostic performance of hs-cTn assays varies substantially in elderly patients, with a suspicion of ACS effecting distinct receiver operating characteristic (ROC)-derived cut-offs.19

The expected decrease in specificity and positive predictive value was recently substantiated by a study in chest pain patients presenting to the accident and emergency (A&E) department that showed a reduced
Acute Coronary Syndromes

### Table 1: Thrombolysis in Myocardial Infarction Risk Score for Patients with Unstable Angina and Non-ST-elevation Myocardial Infarction – Predictor Variables

<table>
<thead>
<tr>
<th>Predictor Variable</th>
<th>Point Value of Variable</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥65 years</td>
<td>1</td>
<td>Risk factors: • Family history of CAD • Hypertension • Hypercholesterolemia • Diabetes • Current smoker</td>
</tr>
<tr>
<td>≥3 risk factors for CAD</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Aspirin use in last 7 days</td>
<td>1</td>
<td>≥2 anginal events in last 24 hours</td>
</tr>
<tr>
<td>Recent, severe symptoms of angina</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Elevated cardiac markers</td>
<td>1</td>
<td>CK-MB or cardiac-specific troponin level</td>
</tr>
<tr>
<td>ST deviation ≥0.5 mm</td>
<td>1</td>
<td>ST depression ≥0.5 mm is significant; transient ST elevation &gt;0.5 mm for &lt;20 minutes is treated as ST-segment depression and is high risk; ST elevation &gt;1 mm for &gt;20 minutes places patients in the STEMI treatment category</td>
</tr>
<tr>
<td>Prior coronary artery stenosis &gt;50%</td>
<td>1</td>
<td>Risk predictor remains valid even if this information is unknown</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Calculated TIMI Risk Score</th>
<th>Risk of ≥1 Primary Endpoint* in ≤14 days</th>
<th>Risk Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 or 1</td>
<td>5%</td>
<td>Low</td>
</tr>
<tr>
<td>2</td>
<td>8%</td>
<td>Low</td>
</tr>
<tr>
<td>3</td>
<td>13%</td>
<td>Intermediate</td>
</tr>
<tr>
<td>4</td>
<td>20%</td>
<td>Intermediate</td>
</tr>
<tr>
<td>5</td>
<td>26%</td>
<td>High</td>
</tr>
</tbody>
</table>

* Primary endpoints: death, new or recurrent MI or need for urgent revascularization

CAD = coronary artery disease; CK-MB = creatine kinase myocardial band; MB = myocardial infarction; NSTEMI = non-ST-elevation myocardial infarction; TIMI risk score = Thrombolysis in Myocardial Infarction risk score. Adapted from Antman, et al., 2000.25

These findings underline the futility of using an absolute threshold level alone and strongly call for additional parameters, such as the kinetics of troponin levels and/or additional biomarkers, for making the diagnosis of MI. Indeed, the former was addressed by a study showing that a doubling of the hs-cTnT concentration within three hours of the first time-point in conjunction with initially elevated hs-TnT levels allowed an increase in the positive predictive value for AMI to 100%.22 Serial testing using hs-Tn assays at zero and six hours after hospitalization increases both sensitivity and specificity, and implementation of a delta criterion (% increase) further enhances specificity.23 Absolute changes of cTn levels determined two hours apart have a significantly higher diagnostic accuracy for AMI than relative changes (area under the ROC curve [AUC] for hs-TnT 0.95 versus 0.76; cardiac troponin I ultra 0.95 versus 0.72).23

Three recent studies analysed the combination of copeptin (the arginine-vasopressin prohormone-derived peptide) in conjunction with hs-cTn for the rapid rule-out of MI. The use of pre-specified cut-offs for both markers was associated with an improvement in the rule-out of MI in patients admitted to the A&E department with a likely diagnosis of NSTEMI, whereas in patients presenting with acute chest pain, initial negative conventional cTnT levels and a non-diagnostic ECG, the rapid rule-out of MI using hs-TnT could not be further enhanced by adding copeptin (continuous) levels.25 For the identification of patients with MI presenting within three hours of onset of chest pain, a high-sensitivity cardiac troponin I (hs-cTnI) assay delivered an AUC of 0.96 alone, with a small but significant improvement to an AUC of 0.97 (p=0.00397) when copeptin was added.26 In all studies, the specificities remained low.

### Risk Stratification of Patients with Acute Coronary Syndrome

The risk stratification of patients with ACS is of paramount clinical importance. Most, but not all, studies that simply compared conventional and sensitive troponin assays found that sensitive troponin assays improve risk prediction of event-free survival at both 30 days and one year.28–31 However, the predictive value of sensitive troponin assays must be regarded in conjunction with risk scores that combine the clinical parameters, ECG findings and basic laboratory parameters that have a well-documented clinical value and are recommended by current guidelines.25–30

Commonly used is the Thrombolysis in Myocardial Infarction (TIMI) risk score, based on the series of TIMI studies for patients with UA/NSTEMI26 (see Table 1) and STEMI, respectively. In turn, the Global Registry of Acute Coronary Event (GRACE) risk score (see Figure 3) is based on registry data and was developed to comprise all ACS entities.33,34 Clinical risk scores (all of which contain conventional troponin plasma concentration) provide the backbone against which novel biomarkers need to show incremental benefit as assessed by statistical methods using c-statistics, integrated discriminating index and net reclassification improvement (NRI). High-sensitivity troponin assays did not improve risk prediction in studies that included both STEMI and NSTEMI patients.22–24 In patients with acute chest pain,25 high-sensitivity troponin assays improved the prediction of death, but not of subsequent AMI, with an improved reclassification of patients (NRI 0.91) after adjustment for the TIMI risk score.25

A recent multimarker analysis in the MERLIN-TIMI 36 trial of 4,352 patients with NSTEMI, identified a hs-cTn net improvement over the clinical TIMI risk score (excluding troponin) with c-index 0.784 versus 0.805 (p=0.005) and NRI 0.389 (p<0.001) for cardiovascular death and similarly for MI, hospitalization for congestive heart failure and the composite endpoint of cardiovascular death and hospitalization for congestive heart failure.35 Furthermore, patients presenting with ACS and reclassified into NSTEMI from UA based on hs-Tn against cTn testing correlated with an increased
risk of major adverse cardiovascular events and significantly improved risk stratification.2,3 In conclusion, if combined with clinical scores, sensitive troponin assays appear to improve risk prediction in NSTEMI–ACS patients but not, or less so, in STEMI patients.

**Clinical Management of Patients with Acute Coronary Syndromes**

As of now, only scarce data exist on the effect of introducing hs-Tn assays into clinical practice with respect to patient management and outcomes after therapeutic intervention. Interestingly, lowering the diagnostic threshold of cardiac troponin I (cTnI) from 0.20 ng/l to 0.05 ng/l by the introduction of a sensitive troponin assay (1,038 patients before and 1,054 after implementation) not only increased the rate of NSTEMI diagnosed in patients with suspected ACS, but also translated into major reductions in morbidity and mortality.23 Future trials will need to examine the benefit of an invasive therapy in AMI patients with elevated troponin, similar to those of the previous era with conventional cTnI.24 A prerequisite is the exploration of quantitative cut-offs for hs-Tn and changes over time (delta criterion) to serve as a guidance for therapeutic interventions.

**Summary and Conclusions**

The availability of hs-cTn tests has improved the diagnostics of patients presenting to the A&E department with chest pain. Nonetheless, clinical judgement has become evermore important for the correct interpretation of test results that integrate both laboratory parameters (absolute values of hs-Tn and the kinetics thereof) with clinical symptoms and ECG signs of myocardial ischemia to make the diagnosis of AMI. The increase in sensitivity of hs-cTn tests at the expense of diminished specificity constitutes a challenge to make the diagnosis (‘rule-in’) of AMI. This important topic is currently addressed in two ways:

- by analyzing the absolute/relative increase in hs-Tn concentration over the time necessary to make the diagnosis of AMI; and
- by combining the hs-Tn test with an ideally disease-specific complementary biomarker to enable the diagnosis of AMI at a single time-point.

Evidence is accumulating that hs-cTn assays improve short- and long-term prediction, at least in NSTEMI patients, beyond clinical risk prediction rules, which include cTn levels measured by conventional assays. In addition, beyond risk estimation for elevated hs-cTn concentration, the role of hs-cTn testing in the choice of therapeutic intervention and its effects on clinical outcomes are being analysed. Finally, the underlying mechanism for the stronger association of elevated troponin levels with structural heart disease events rather than with atherothrombotic events is of major interest.

---